Návrh dispozičního řešení penzionu pro starší spoluobčany a jeho začlenění do konkrétní obytné zóny

Prezenční222 - Katedra městského stavitelstv

Structural Diversity of Copper(II) Complexes with 9-Deazahypoxanthine and Their in Vitro SOD-Like Activity

Two structurally different copper(II) complexes of the compositions [{Cu(9dhx)(H2O)3}2(µ-SO4)2] (1) and [Cu(9dhx)2(H2O)2(NO3)2]·H2O (2), involving 9-deazahypoxanthine (9dhx; 6-oxo-9-deazapurine; 9-deazahypoxanthine), have been prepared and characterized by elemental analysis, infrared and electronic spectroscopy, electrospray ionisation (ESI) mass spectrometry, thermogravimetric (TG) and differential thermal (DTA) analyses, and cyclic voltammetry. The X-ray structures of complexes 1 and [Cu(9dhx)2(H2O)2(NO3)2] (2a) revealed the distorted octahedral geometry in the vicinity of the copper(II) atoms, with the NO5 and N2O4 donor set, respectively. In the dimeric compound 1, the {Cu(9dhx)(H2O)3}2 units are bridged by sulfate groups with the Cu···Cu separation being 5.3446(2) Å. In both structures the 9dhx ligands are coordinated through the N3 atoms of the pyrimidine moieties. The SOD-like activity of complexes 1 and 2 was evaluated in vitro showing moderate effect, with the IC50 values equal to 18.20, and 53.33 μM, respectively

A pathway for the preparation of complexes 1–5.

<p>A pathway for the preparation of complexes 1–5.</p

¹H and ¹³C NMR coordination shifts (Δδ = δ_complex – δ_ligand; ppm) of <i>O</i>-substituted 9-deazahypoxanthine moiety atoms in complexes <b>1</b>–<b>5</b>.

<p>¹H and ¹³C NMR coordination shifts (Δδ  =  δ_complex – δ_ligand; ppm) of <i>O</i>-substituted 9-deazahypoxanthine moiety atoms in complexes <b>1</b>–<b>5</b>.</p

Histological evaluation of inflammatory response in tissue sections of the hind paw, stained with Hematoxylin – eosin (40x magnification).

<p>Tissue exposed to 25% DMSO (control; <b>A</b>) and complex <b>5</b> (<b>C</b>) with the acute inflammatory reaction dermis and hypodermis with a massive infiltrate of neurophils (PMN); tissue exposed to complex <b>2</b> (<b>B</b>) and Indomethacin (<b>D</b>) with the inflammatory reaction in the hypodermis with scarce PMN infiltrate.</p

Schematic representations of <i>O</i>-substituted 9-deazahypoxanthine derivatives (HL_1–5) used as the ligands in complexes 1–5.

<p>Schematic representations of <i>O</i>-substituted 9-deazahypoxanthine derivatives (HL_1–5) used as the ligands in complexes 1–5.</p

The results of <i>in vitro</i> cytotoxicity of complexes1–5 and <i>cisplatin</i> against variety of human cancer and healthy cell lines.

<p>Cells were treated with the tested compounds for 24 h; measurements were performed in triplicate, and cytotoxicity experiments were repeated on three different cell passages; data are expressed as IC₅₀±S.E. (µM).</p><p>n.d. – not determined; asterisk (*) symbolizes significant difference (p<0.05) in <i>in vitro</i> cytotoxicity of <b>1</b>–<b>5</b> as compared with <i>cisplatin</i>.</p><p>The results of <i>in vitro</i> cytotoxicity of complexes1–5 and <i>cisplatin</i> against variety of human cancer and healthy cell lines.</p

The molecular structure of 6-phenethyloxy-9-deazapurine (HL₅), showing the atom numbering scheme and N–H⋅⋅⋅N and C–H⋅⋅⋅O non-covalent bonding (dashed lines).

<p>Non-hydrogen atoms are displayed as ellipsoids at the 50% probability level.</p

The time-dependent profile of antiedematous activity of complexes 2, 4 and 5, and Indomethacin.

<p>The time-dependent profile of antiedematous activity of complexes 2, 4 and 5, and Indomethacin.</p